Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)

Exclusion Criteria

• •Must not have known hypersensitivity to MK-8776 or cytarabine or to any of their excipients or have received therapy with another Checkpoint kinase 1 (CHK1) inhibitor.
• •Must not have persistent, unresolved Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v 3.0) ≥ Grade 2 drug-related toxicity (except alopecia, erectile impotence, hot flashes, decreased libido, hematologic toxicity) associated with previous treatment.
• •Must not have known human immunodeficiency virus (HIV), hepatitis B or hepatitis C, or have a known history of liver cirrhosis or active alcohol abuse.
• •Must not be New York Heart Association (NYHA) Class III (has marked limitation in activity due to symptoms, even during less than ordinary activity \[e.g. walking short distances \>20-100 m\]; is comfortable only at rest) or Class IV (has severe limitations; experiences symptoms even while at rest; mostly bed bound).
• •Must not have undergone major surgery within 3 weeks prior to first study drug administration after enrollment.
• •Must not have known active central nervous system (CNS) or leptomeningeal leukemia.
• •Must not have received radiation therapy within 2 weeks prior to first study treatment administration after enrollment or radiation therapy to \>25% of bone marrow.
• •Must not have received more than 4 prior induction regimens.
• •Must not have a peripheral blast count ≥50,000/mm\^3.
• •Must not have active, uncontrolled graft versus host disease (GVHD) post-allogeneic stem cell transplant.
• •Must not have had any of the following within 6 months prior to first study treatment administration after enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or seizure disorder.
• •Must not have a known bleeding diathesis, e.g. hemophilia, or disseminated intravascular coagulation.
• •Must not have an active, uncontrolled infection.
• •Must not have a history of cytarabine-related neurotoxicity.
• •Must not have a baseline corrected QT (QTc) interval \>470 msec (i.e. CTCAE v 3.0 Grade ≥2).
• •Must not currently be a smoker and/or must not be likely to smoke during the study.
• •Females must not be breast-feeding, pregnant, or intend to become pregnant.